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Collagen VI is an extracellular matrix protein ex-
pressed in several tissues including skeletal
muscle. Mutations in COL6A genes cause Beth-
lem Myopathy (BM), Ullrich Congenital Muscular
Dystrophy (UCMD) and Myosclerosis Myopathy
(MM). Collagen VI deficiency causes increased
opening of the mitochondrial permeability transi-
tion pore (mPTP), leading to ultrastructural and
functional alterations of mitochondria, amplified
by impairment of autophagy. Here we report for
the first time ultrastructural studies on muscle
biopsies from BM and UCMD patients, showing
swollen mitochondria with hypodense matrix,
disorganized cristae and paracrystalline inclu-
sions, associated with dilated sarcoplasmic retic-
ulum and apoptotic changes. These data were
supported by scanning electron microscopy
analysis on BM and UCMD cultured cells, show-
ing alterations of the mitochondrial network. Mor-
phometric analysis also revealed a reduced short
axis and depicted swelling in about 3% of mito-
chondria. These data demonstrate that mitochon-
drial defects underlie the pathogenetic mecha-
nism in muscle tissue of patients affected by col-
lagen VI myopathies.
KEY WORDS: collagen VI, mitochondria, mPTP,
scanning electron microscopy back-scattered imaging,
transmission electron microscopy.
Introduction
Collagen VI (ColVI) is a protein widely expressed in
the extracellular matrix (ECM) of most connective tis-
sues where it contributes to the maintenance of tis-
sues integrity and function1. It forms a microfibrillar
network in several organs including skeletal muscle
where it is mainly localized just outside the basement
membrane2. ColVI is composed by three chains (al-
pha1, alpha2, alpha3), encoded by different genes
(COL6A1, COL6A2 and COL6A3, respectively), which
associate inside the cell in a stoichiometric ratio to
form a triple helical monomer which assembles in
dimers and tetramers stabilized by disulfide bonds3.
After secretion, tetramers associate end-to-end, form-
ing typical 100 nm periodic beaded microfibrils by in-
teractions of their non-collagenous domains. Recent-
ly, three novel ColVI chains (alpha4, alpha5, and al-
pha6) were discovered, which resemble alpha3 but
have a more restricted tissue distribution4. Novel
ColVI chains may replace alpha3, probably forming al-
pha 1-2-4, alpha 1-2-5, or alpha 1-2-6 heterotrimers4.
Mutations in COL6A1, COL6A2 and COL6A3 genes
cause a group of inherited muscular dystrophies: Ull-
rich Congenital Muscular Dystrophy (UCMD), Bethlem
Myopathy (BM) and Myosclerosis Myopathy (MM).
UCMD is a severe disorder characterized by congeni-
tal muscle weakness with axial and proximal joint con-
tractures and coexisting distal joint hypermobility5. BM
is an autosomal dominant or recessive disorder char-
acterized by slowly progressive axial and proximal
muscle weakness with finger flexion contractures6.
MM is a recessive disorder characterized by progres-
sive all-joint contractures7.
Collagen VI myopathies share a mitochondrial dys-
function due to the deregulation of the permeability
transition pore (mPTP)8. In vitro studies on BM and
UCMD mitochondria show an abnormal depolarization
unmasked by the employment of oligomycin, an ATP
synthase inhibitor9. The identification of the pathogen-
ic mechanism of ColVI myopathies paved the way to
several treatments to rescue the mitochondrial defect,
using compounds or genetic manipulations. The nor-
malizing effect of cyclosporin A (CsA) on mPTP pore
was demonstrated in vitro and ex vivo conditions9,
then employed in a pilot clinical trial10. CsA in fact in-
hibits the mPTP through the binding and the enzymat-














over, Debio 025, a non-immunosuppressive derivative
of CsA successfully rescued the mPTP function12. A
different approach was adopted by inactivating the
Ppif gene encoding cyclophilin D in the Col6a1 -/-
mouse model, confirming the pathogenic role of
mPTP opening13. A strong mitochondrial involvement
has been found also in the Col6a1 -/- mouse model
which showed a defective autophagy14. The impaired
removal of defective mitochondria amplifies the de-
fect, which is worsened by excessive oxidative stress
and Ca2+ accumulation in the mitochondria. The au-
tophagy defect correction by a low protein diet demon-
strated a morphological mitochondrial rescue in terms
of size and decrease of swelling14. 
Additional evidences for the mitochondrial involve-
ment in the pathogenesis of collagen VI-related  my-
opathies derived from zebrafish animal model, geneti-
cally manipulated on col6a1 gene to reproduce both
the mild phenotype (BM-like) and the strong pheno-
type (UCMD-like)15. This resulted a good model to
study because of the mPTP structural and functional
homology between zebrafish and mammals16. Treat-
ment with CsA was in fact effective on both pheno-
types, restoring mitochondrial abnormalities and de-
creasing the apoptotic rate, together with a strong im-
provement of motor function15. 
Here we report for the first time ultrastructural studies
on muscle biopsies from BM and UCMD patients, pre-
senting swollen mitochondria with hypodense matrix,
disorganized cristae and paracrystalline inclusions as-
sociated with dilated sarcoplasmic reticulum and
apoptotic changes. The same mitochondrial alter-
ations are maintained in BM and UCMD cell cultures,
which  can be regarded as a reliable model for the
study of these diseases.
Materials and Methods
Patients
Skeletal muscle biopsies from three healthy subjects,
two UCMD patients, two BM patients and one MM pa-
tient were collected; samples were frozen in pre-
chilled isopentane and stored in liquid nitrogen. Pa-
tients were diagnosed by genetic, biochemical and im-
munohistochemical analysis: UCMD-1, UCMD-2 and
BM patients were described by Merlini et al.17 (patient
1, patient 3 and patient 5; respectively); MM patient
was described by Merlini et al.7. All participants pro-
vided written informed consent, and approval was ob-
tained from the Ethics Committee of the Rizzoli Or-
thopaedic Institute (Bologna, Italy).
Primary muscle-derived cell cultures
Primary cell cultures derived from muscle biopsies of
control, BM patient and UCMD patients were estab-
lished and maintained in Dulbecco’s modified Eagle’s
medium (DMEM) plus 20% fetal calf serum (FCS)
and antibiotics (penicillin, streptomycin and ampho-
tericin B).
Transmission electron microscopy
Muscle biopsies were processed for electron mi-
croscopy analysis. Muscle tissue was fixed with 2.5%
glutaraldehyde-0.1 M cacodylate buffer pH 7.4 for 3 h
at 4 °C, post-fixed with 1% osmium tetroxide (OsO4)
in cacodylate buffer for 2h, and dehydrated in an
ethanol series, infiltrated with propylene oxide and
embedded in Epon 812 resin. 
Muscle-derived cells were grown in DMEM supple-
mented with 20% FCS until confluence, fixed with
2.5% glutaraldehyde in cacodylate buffer 0.1 M, pH
7.2, and post-fixed with 1% osmium tetroxide in ca-
codylate buffer 0.1 M, pH 7.3. After detaching with
propylene oxide, the cells were centrifuged and em-
bedded in Epon 812. Utrathin sections were stained
with uranyl acetate and lead citrate and observed with
a Philips EM400 operating at 100 kV.
Scanning electron microscopy back-scattered
imaging
Cu-Pb staining solution was prepared by mixing 20 ml
of 4.6% trisodium citrate, 2ml of 33% lead nitrate, and
0.5 ml of 10% copper sulfate (pH 9), and used undilut-
ed. Cells were fixed with 2.5% glutaraldehyde–0.1M
cacodylate buffer pH 7.3 for 1 h at 4°C. After washing
with 0.1M cacodylate buffer pH 7.3, the coverslips
were brought to room temperature, washed three
times with distilled water and incubated with Cu–Pb
solution at 4°C overnight. The samples were then
brought to room temperature, washed three times with
distilled water and post-fixed with 1% osmium tetrox-
ide in 0.1M cacodylate buffer for 1 h at room tempera-
ture. After rinsing with 0.1M cacodylate buffer and
then with distilled water, the samples were dehydrated
in an ethanol series and critical point dried. The cover-
slips carrying cells were then mounted on aluminum
stubs with silver adhesive paint, coated with spectro-
graphic carbon by vacuum evaporation in an Ewards
E 306 apparatus, and observed at 0° tilt angle with a
Cambridge Stereoscan 200 scanning electron micro-
scope equipped with an Oxford Tetra solid state BSE
detector. Acceleration voltage was set at 30 kV and
WD at 15 mm.
Immunofluorescence analysis
For immunofluorescence analysis in vitro, muscle
cells were grown onto coverslips, fixed with cold
methanol, washed with PBS and incubated with rabbit
anti-desmin (Monosan Technology) and Mito Tracker
Red (Life Technologies). Nuclei were counterstained
with DAPI. Samples were mounted with an anti-fading
reagent (Molecular Probes) and observed with a
Nikon epifluorescence microscope. 
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By transmission electron microscopy, we investigated
the ultrastructural alterations in muscle fibers of colla-
gen VI-related myopathies patients. In UCMD pa-
tients muscle fibers we noticed a strong enlargement
of sarcoplasmic reticulum associated with mitochon-
dria abnormalities including swelling and cristae with
a tubular arrangement. Mitochondrial alterations were
also detected in muscle fibers of MM and BM pa-
tients. The unusual presence of osmiophilic bodies
and paracrystalline inclusions was found in several
non necrotic muscle fibers, as indicated by the nor-
mal organization of myofibrils (Fig. 1A). Interestingly,
muscle fibers of UCMD patients showed also the
presence of nuclear changes consistent with apopto-
sis, as indicated by the peripheral chromatin conden-
sation and irregular shape (Fig. 1B). 
To better characterize the mitochondrial network, mus-
cle cell cultures were studied by using the mitochondri-
on-selective probe MitoTracker18. MitoTracker is a fluo-
rescent dye that stains mitochondria in live cells and its
accumulation is dependent upon membrane potential.
Consistent with a latent mitochondrial dysfunction9,
UCMD and BM muscle cells, identified by anti-desmin
antibody, displayed  mitochondrial changes consistent
with fragmentation as indicated by the presence of a
perinuclear punctuate pattern with respect to the elon-
gated and well developed network of control cells (Fig.
2A). Back scattered imaging of cultured cells allowed to
clearly monitor both organization and extension of the
mitochondrial reticulum by copper-lead salt solution
which specifically stains the mitochondria mem-
branes19. BM and UCMD patient cells showed reduced
mitochondrial branching, increased mitochondria frag-
mentation and swelling, and irregular thickness, with re-
spect to the control which displayed a regular long and
branched mitochondrial reticulum (Fig. 2B). A morpho-
logical analysis of the mitochondrial reticulum was also
conducted on resin embedded samples. In agreement
with the scanning electron microscopy analysis, UCMD
and BM mitochondria showed an irregular shape and
changes consistent with mitochondrial swelling (Fig.
3A). These features were also confirmed by morpho-
metric analysis (Fig. 3B); in fact, UCMD and BM pa-
tients displayed a high percentage of smaller mitochon-
dria as compared to control (mitochondria with short ax-
is <200nm: 29.3% in control, 46.55% in BM patient and
61.21% in UCMD patient) and also a significant in-
crease of mitochondria with short axis >600nm: 0,86%
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Figure 1. (A) Transmission elec-
tron microscopy analysis of Epon-
embedded muscular biopsies
from UCMD, BM and MM pa-
tients. All samples display ultra-
structural alterations: sarcoplas-
mic reticulum enlargement asso-
ciated with mitochondria abnor-
malities as well as osmiophilic
bodies and paracrystalline inclu-
sions. Scale bar, 0.5 µm. (B) A
muscle fiber of a UCMD patient
showing nuclear changes consis-
tent with apoptosis, such as an ir-
regular shape and chromatin con-














in control, 2.58% in BM and UCMD patients, which can
be interpreted as swelling events (Fig. 3B). 
Discussion
Mitochondria have been recently recognized as new
leading actor in collagen VI myopathies. The first ob-
servation came from Irwin et al.20 which demonstrated
the existence of a latent mitochondrial dysfunction in a
knockout mouse model (Col6a1-/-). The mitochondrial
defect was also observed in myofibers isolated from
muscle of Col6a1-/- mice after the addition of
oligomycin, thus inhibiting ATP synthase and dropping
the mitochondrial membrane potential20. 
Until now, the alterations responsible of the patho-
genic mechanism of collagenVI myopathies have
been described in animal models (Col61-/- knockout
mouse and col6 mutant zebrafish) and in patient cell
cultures. Here we report for the first time that mito-
chondrial abnormalities are also present in mature
muscle fibers of UCMD, BM and MM patients, indi-
cating that mitochondrial defect underlie the patho-
genetic mechanism in muscle tissue of patients af-
fected by collagen VI myopathies. Morphometric
analysis and scanning electron microscopy of mito-
chondrial network in UCMD and BM cultured cells
suggests alterations of mitochondrial reticulum with a
tendency to swelling and fragmentation in collagen
VI-deficient cells. 
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Figure 2. (A) Mitotracker red labelling on
control, UCMD and BM muscle cells, iden-
tified by anti-desmin labelling (green). In
these representative images the mitochon-
drial network appears fragmented and dis-
continuous in both patients as compared to
that of control cells. Scale bar, 20 µm. (B)
This pattern is confirmed by back scattered
imaging of muscle-derived cell cultures
from BM and UCMD patients. Both pa-
tients display a less developed mitochon-
drial network compared to the long and















Altered mitochondrial morphology associated with
mPTP dysfunction have been reported in cultured
muscular cells of patients affected by collagen VI my-
opathies9. Muscular dystrophies linked to collagen VI
deficiency show  dysfunctional mitochondria and
spontaneous apoptosis, leading to myofiber degener-
ation. 
The mPTP latent dysfunction was observed moreover
both in muscle cells and in muscle fibroblasts from
UCMD and BM patients21, confirming that mitochondr-
ial alteration is a key feature of collagen VI-related
diseases. Protracted mPTP opening can disable res-
piration, producing toxic oxidative species and mediat-
ing leakage of proteins into the cytoplasm that can ac-
tivate apoptosis or necrosis22. Interestingly, we re-
cently reported that DMD muscle cells and
melanocytes displayed the oligomycin-induced mito-
chondrial depolarization23.
The autophagy defect due to collagen VI deficiency in
the Col6a1 -/- mouse model and BM and UCMD pa-
tients leads furthermore to the accumulation of altered
mitochondria14. Defect of the autophagic system
cause a strong impairment in the degradative mecha-
nism of abnormal organelles14. 
The data here reported confirm the importance of mi-
tochondria in the pathogenesis of ColVI muscular dys-
trophies. The collagen VI-mitochondria connection re-
quires the understanding of the mechanisms by which
mitochondria sense alterations in the ECM. The data
here reported, which indicate that in tissues and cell
cultures from ColVI-affected patients mitochondria un-
dergo not only swelling, possibly due to the Ca2+ over-
load, but also fragmentation of their network, suggest
that additional players could be involved. Further stud-
ies should confirm the hypothesis that the regulation
of mitochondrial distribution and that of the cytoskele-
tal three-dimensional structure, which affect the sensi-
tivity of cells to apoptotic stimuli24, depend on the
small GTPases that modulate the fusion-fission ma-
chinery25.
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Figure 3. (A) Transmission electron microscopy analysis of Epon-embedded cell cultures from control, BM and UCMD pa-
tients. Patients’ cells show morphological alteration consisting in irregularly shaped and swollen mitochondria. Scale bar, 0.8
µm. (B) Morphometric analysis of the mitochondrial short axis. UCMD and BM patients display an higher percentage of
smaller mitochondria as compared to control (mitochondria with short axis measuring less than 200nm: 29.3 in control,
46.55 in BM patient and 61.21 in UCMD patient) and also a clear increase of mitochondria percentage with short axis mea-
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